

## **Reviewer 1:**

### **SPECIFIC COMMENTS TO AUTHORS**

thank you for inviting me to review the case report. the discussion should be improved and compairs your result with other studies. please describe the drug history. there are some tiny grammatical issues that should.

Dear reviewer 1:

Thank you for your review. According to your suggestion, we added the comparison with other studies in the discussion section of the article. In the discussion section, we added clinical studies on targeted drugs and immunotherapy in metastatic PPGLs, such as the treatment of patients in the study treated with sunitinib (page 18-19). This article summarizes the drug history of this patient with malignant paraganglioma (page 20-21). The problems about the language quality in this article have been corrected by the polishing company. Thank you again!

Best wishes!

Reviewer 2:

### **SPECIFIC COMMENTS TO AUTHORS**

It was a pleasure going through the manuscript. It loos great still I have few suggestions. When was her last follow up and what was her condition? Had you had a follow up after apatinib? In conclusion section author has described the case. I think it is better to provide your opinion in such case management standing on the base of this case. Please recheck reference 1 for name of authors hitting the DOI number or surf the original journal site you can get it. Felix Frankel There are few typological errors throughout the manuscript. Please check and correct.

Dear reviewer 2:

The patient diagnosed with malignant paraganglioma accepted apatinib

almost 3 months, died of multiple organ failure. In the conclusion section, we add a perspective on the management of PPGLs (page 22). As for the format of reference 1, we have modified it, and the author of this reference was anonymous. The problems about the language quality in this article have been corrected by the polishing company. Thank you again!

Best wishes!